Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health. Its business segments include the development of peptide-based therapeutics targeting obesity, rare diseases such as congenital hyperinsulinism and short bowel syndrome, and chronic inflammatory conditions. Main products and candidates in its pipeline include petrelintide, a long-acting amylin analog for weight loss; survodutide, a glucagon/GLP-1 receptor dual agonist for obesity and MASH, which is licensed to Boehringer Ingelheim; ZP9830, a Kv1.3 ion channel blocker for autoimmune diseases; ZP6590, a GIP receptor agonist for obesity; dasiglucagon, a glucagon analog for congenital hyperinsulinism; and glepaglutide, a GLP-2 analog for short bowel syndrome. The company serves patients with metabolic disorders and rare diseases. Notable partnerships include a collaboration and license agreement with Generate Biomedicines to develop protein therapeutics engineered with AI for metabolic diseases.

Summarised from the company's own disclosures

Industry Biotechnology Homepage zealandpharma.com
Sector Healthcare IR page —
Tags
obesity, metabolic health, peptide therapeutics, rare diseases, autoimmune diseases, clinical development, petrelintide, survodutide, ZP9830, ZP6590, dasiglucagon, glepaglutide, ZP8396, Boehringer Ingelheim, Generate Biomedicines
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 55.1%
ROI 42.7%
ROIC 47.0%
Profit margin 70.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 2.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 9.215B 62.69M 342.78M 103.98M 292.56M
Net profit 6.455B -1.079B -703.73M -1.202B -1.018B

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Zealand Pharma (ticker ZEAL), listed in Denmark.

ETFs Holding Zealand Pharma

ETF Weight in ETF Shares Market value As of
OZEM 3.04% 50,254 $ 1.699M Nov 17, 2026
HRTS 0.44% 5,223 $ 243.479K Aug 31, 2026
DISV 0.07% 104,241 $ 3.72M Nov 12, 2026
AVDS 0.07% 7,073 $ 246.988K Nov 16, 2026
DXIV 0.05% 3,437 $ 122.671K Nov 12, 2026
DFIS 0.03% 50,039 $ 1.786M Nov 12, 2026
DFSI 0.03% 10,191 $ 363.73K Nov 12, 2026
AVDE 0.03% 172,566 $ 6.026M Nov 16, 2026
DFIC 0.02% 73,948 $ 2.639M Nov 12, 2026
DFAX 0.01% 47,227 $ 1.686M Nov 12, 2026
DFAI 0.00% 20,977 $ 748.696K Nov 12, 2026